GLP-1 Receptor Agonists Linked to Reduced Uveitis Risk
A new cohort study published in JAMA Ophthalmology suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely used for managing diabetes and obesity, may be associated with a lower risk of uveitis compared with matched controls.[1] These findings hint at potential anti-inflammatory effects of GLP-1 RAs beyond their metabolic benefits, offering an avenue for future research into ocular inflammatory disorders.
The retrospective cohort study examined prescription data and linked ocular outcomes, finding that patients using GLP‑1 RAs had a reduced incidence of uveitis relative to non-users. Although specific hazard ratios and absolute risk differences were not publicly available in the summary, the results suggest that these medications may exert protective influence against uveitic processes.
Clinical and Scientific Significance
Beyond glycemic control: GLP‑1 RAs are already known for their roles in improving cardiovascular and metabolic health. This study uncovers an anti-inflammatory signal in the eye, which could broaden their therapeutic potential.
Implications for uveitis prevention or adjunctive therapy: If confirmed, GLP‑1 RAs might offer additional benefits for patients at risk of ocular inflammation, especially those with comorbid diabetes.
Mechanistic intrigue: Preclinical research has highlighted GLP‑1 RAs’ neuroprotective and anti‑inflammatory properties across various tissues.[2]
The authors stated that future prospective trials are essential to determine causality and whether GLP-1 RAs could play a role in uveitis management. Since GLP-1 RAs are often used in populations with obesity and metabolic disease, careful consideration of confounders and baseline risk profiles is crucial for interpreting the results.
References
1. Mohan N, Srivastava SK, Schulgit MJ, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis. JAMA Ophthalmol. Published online August 28, 2025. doi:10.1001/jamaophthalmol.2025.2822
2. Xie Z, Yang Z, Tian D, Cheb Y. Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact. Frontiers in Pharmacology. 2025;16:1618079. doi:10.3389/fphar.2025.1618079